Expertise in
5
conditions

Tamara Intermesoli

Bergamo, IT 
Expertise in
5
conditions
Bergamo, IT 

Overview

Tamara Intermesoli practices practicing medicine in Bergamo, Italy.

Ms. Intermesoli is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Leukemia, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 46 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Bergamo, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Front-line Treatment of Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia With Ponatinib, a New Potent Tyrosine Kinase Inhibitor.
Front-line Treatment of Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia With Ponatinib, a New Potent Tyrosine Kinase Inhibitor.
Enrollment Status: Completed
Publish Date: November 30, 2021
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia With Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategy
National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia With Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategy
Enrollment Status: Completed
Publish Date: September 08, 2021
Intervention Type: Procedure, Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

46 Total Publications

How deep is deep enough? The importance of the detection limits of the CML minimal residual disease gDNA assay.
How deep is deep enough? The importance of the detection limits of the CML minimal residual disease gDNA assay.
Journal: Cell death discovery
Published: March 05, 2026

Frequently Asked Questions about Tamara Intermesoli

Is Tamara Intermesoli a top-rated expert for Chronic Myelogenous Leukemia (CML)?

MediFind is an objective health platform that identifies experts based on real-world data. Tamara Intermesoli is classified as an Distinguished expert for Chronic Myelogenous Leukemia (CML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Tamara Intermesoli participate in research or clinical trials?

Yes. Tamara Intermesoli has published 46 articles and abstracts on conditions like Chronic Myelogenous Leukemia (CML). You can view a list of Tamara Intermesoli's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Intermesoli's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile